42.63
2.36%
-1.03
Handel nachbörslich:
40.50
-2.13
-5.00%
Schlusskurs vom Vortag:
$43.66
Offen:
$43.95
24-Stunden-Volumen:
125.43K
Marktkapitalisierung:
$2.68B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.01M
KGV:
-36.46
EPS:
-1.1692
Netto-Cashflow:
$-42.78M
1W Leistung:
-0.49%
1M Leistung:
-7.81%
6M Leistung:
+6.10%
1J Leistung:
+57.54%
MoonLake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
MoonLake Immunotherapeutics
Sektor
Branche
Telefon
-
Adresse
Dorfstrasse 29, Zug
MoonLake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-12-08 | Eingeleitet | Citigroup | Buy |
2023-11-02 | Eingeleitet | Stifel | Buy |
2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
2023-08-31 | Eingeleitet | Needham | Buy |
2023-06-15 | Eingeleitet | Barclays | Equal Weight |
2023-05-01 | Eingeleitet | Guggenheim | Buy |
2023-03-22 | Eingeleitet | Wedbush | Outperform |
2023-03-09 | Eingeleitet | BTIG Research | Buy |
2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
2022-11-11 | Eingeleitet | Jefferies | Buy |
2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
MoonLake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire Inc.
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
GlobeNewswire Inc.
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
GlobeNewswire Inc.
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
GlobeNewswire Inc.
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
Zacks Investment Research
Finanzdaten der MoonLake Immunotherapeutics-Aktie (MLTX)
MoonLake Immunotherapeutics (MLTX) Nettogewinn 2024
MLTX betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -36.01 Millionen US-Dollar, was einem Anstieg von +34.79% im Vergleich zum Vorjahr entspricht.
MoonLake Immunotherapeutics (MLTX) Free Cashflow 2024
MLTX verzeichnete einen Free Cashflow der letzten 12 Monate von -42.78 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Anstieg von +23.49% im Vergleich zum Vorjahr entspricht.
MoonLake Immunotherapeutics (MLTX) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von MLTX für die letzten 12 Monate betrug -0.74 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Wachstum von +45.19% im Vergleich zum Vorjahr entspricht.
MoonLake Immunotherapeutics-Aktie (MLTX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Santos da Silva Jorge | Chief Executive Officer |
Feb 28 '24 |
Sale |
55.00 |
56,065 |
3,083,575 |
2,987,554 |
Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
31,910 |
1,755,050 |
2,925,573 |
Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
28,090 |
1,544,950 |
41,981 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 27 '24 |
Sale |
55.00 |
62,810 |
3,454,550 |
3,043,619 |
Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,491 |
1,622,005 |
2,957,483 |
Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,431 |
1,618,705 |
70,071 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 21 '24 |
Sale |
55.27 |
1,125 |
62,179 |
3,106,429 |
Reich Kristian | Chief Scientific Officer |
Feb 21 '24 |
Sale |
55.30 |
569 |
31,466 |
99,502 |
Reich Kristian | Chief Scientific Officer |
Feb 21 '24 |
Sale |
55.31 |
509 |
28,153 |
2,986,974 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 20 '24 |
Sale |
57.44 |
20,000 |
1,148,800 |
3,107,554 |
Kapitalisierung:
|
Volumen (24h):